SOX9 Reprogramming of iPSCs for Rapid OPC Differentiation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating oligodendrocyte progenitor cells (OPCs) from induced pluripotent stem cells (iPSCs) are inefficient, lengthy, and prone to forming undesired cell types, with low differentiation efficiency and high immune response risks, limiting their application in treating demyelinating disorders like multiple sclerosis.

Innovation Solution

The use of SOX9-mediated direct reprogramming of iPSCs to generate OPCs within 1 to 8 days, with high efficiency and immunoprotection through secretion of anti-inflammatory cytokines, such as IL-10 and IFNβ, without requiring media regimen optimization.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If current methods are used to generate OPCs from iPSCs, then cell differentiation can occur, but the process is lengthy and inefficient with low differentiation efficiency

Engineering Contradiction:

ImproveOPC generation efficiencyVSAvoidtime required for OPC generation

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent changes the biochemical parameters by introducing specific transcription factors (SOX9, BRN3A, ASCL1) to alter the differentiation pathway. This transforms the slow, inefficient natural differentiation process into a rapid, high-efficiency process that generates OPCs in 1-8 days with 40-90% efficiency, directly resolving the contradiction between productivity and time loss

Inventive Principle:

Principle #35Parameter changes

2Manufacturing precision

If current differentiation methods are used, then OPCs can be generated, but undesired cell types are formed with low precision

Engineering Contradiction:

Improvecell type differentiation precisionVSAvoiddifferentiation efficiency

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies local quality by using cell-type-specific transcription factors that act on particular genetic pathways. SOX9, BRN3A, and ASCL1 each bind to specific DNA sequences and regulate expression of genes unique to the OPC lineage, ensuring that differentiation is precisely directed toward the desired cell type while preventing formation of undesired cell types, thus achieving both high precision and high efficiency

Inventive Principle:

Principle #3Local quality

3Reliability

If OPCs are generated for demyelinating disorder treatment, then myelin sheath rebuilding can occur, but immune response risks are high

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidimmune response risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent uses transcription factors as intermediaries to mediate the transformation of iPSCs into OPCs. These transcription factors (SOX9, BRN3A, ASCL1) act as molecular mediators that precisely control the differentiation process, ensuring that the generated cells are functional OPCs capable of myelin sheath rebuilding while maintaining immunocompatibility, thus achieving both treatment effectiveness and reduced immune response risk

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12509660B2SOX9-induced oligodendrocyte progenitor cells

Publication Date: 2025.12.30 PRESIDENT & FELLOWS OF HARVARD COLLEGE

AI summary

Provided herein is a differentiation agent that consists essentially of SOX9 for the production of oligodendrocyte progenitor cells (OPCs) from pluripotent stem cells (PSC). Also provided herein are methods of producing the PSCs and methods of using the PSCs to produce OPCs and oligodendrocytes.